Bal Pharma
CEP Certificates (EDQM COS List)

Bal Pharma

CEP Database

Certificates of Suitability to the European Pharmacopoeia (CEP), issued by the EDQM.

Chemical India
  • Total Records 8
  • Latest End Date 2020-06-03
  • Data Source EDQM
  • Last Updated 2023-03-02
All
8
View
Valid
7
View
Expired
1
View
Company Overview

Company

Bal Pharma

Country

India

Social Profiles

Company Snapshot

Bal Pharma

5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bangalore, Karnataka

India

www.balpharma.com/ bulkdrugs@balpharma.com View on Map
CEP Records Timeline (8 records)
2023
02 Mar
Chemical Valid

Product

Adapalene

Substance

BAL PHARMA LIMITED Bangalore IN

Certificate No.

R1-CEP 2016-309 - Rev 00

Substance No.

2445

Issue Date

2023-03-02

End Date

-

Country

India

Identifiers

Certificate No.: R1-CEP 2016-309 - Rev 00
Substance No.: 2445

2015
03 Jun
Chemical Expired

Product

Gliclazide

Substance

BAL PHARMA LIMITED Bangalore IN

Certificate No.

R0-CEP 2013-038 - Rev 00

Substance No.

1524

Issue Date

2015-06-03

End Date

2020-06-03

Country

India

Identifiers

Certificate No.: R0-CEP 2013-038 - Rev 00
Substance No.: 1524

2026
06 Mar
Chemical Valid

Product

Deferasirox

Substance

BAL PHARMA LIMITED Bengaluru IN

Certificate No.

CEP 2024-364 - Rev 00

Substance No.

2933

Issue Date

2026-03-06

End Date

-

Country

India

Identifiers

Certificate No.: CEP 2024-364 - Rev 00
Substance No.: 2933

2025
25 Sep
Chemical Valid

Product

Amiloride hydrochloride dihydrate

Substance

BAL PHARMA LIMITED Bengaluru IN

Certificate No.

CEP 2022-337 - Rev 00

Substance No.

651

Issue Date

2025-09-25

End Date

-

Country

India

Identifiers

Certificate No.: CEP 2022-337 - Rev 00
Substance No.: 651

2025
30 Jul
Chemical Valid

Product

Gliclazide

Substance

BAL PHARMA LIMITED Bengaluru IN

Certificate No.

CEP 2001-273 - Rev 08

Substance No.

1524

Issue Date

2025-07-30

End Date

-

Country

India

Identifiers

Certificate No.: CEP 2001-273 - Rev 08
Substance No.: 1524

2025
30 Jul
Chemical Valid

Product

Ebastine

Substance

BAL PHARMA LIMITED Bengaluru IN

Certificate No.

CEP 2013-051 - Rev 04

Substance No.

2015

Issue Date

2025-07-30

End Date

-

Country

India

Identifiers

Certificate No.: CEP 2013-051 - Rev 04
Substance No.: 2015

2025
30 Jul
Chemical Valid

Product

Gliclazide, AP

Substance

BAL PHARMA LIMITED Bengaluru IN

Certificate No.

CEP 2013-039 - Rev 04

Substance No.

1524

Issue Date

2025-07-30

End Date

-

Country

India

Identifiers

Certificate No.: CEP 2013-039 - Rev 04
Substance No.: 1524

2025
11 Jul
Chemical Valid

Product

Benzydamine hydrochloride

Substance

BAL PHARMA LIMITED Bengaluru IN

Certificate No.

CEP 2021-325 - Rev 02

Substance No.

2759

Issue Date

2025-07-11

End Date

-

Country

India

Identifiers

Certificate No.: CEP 2021-325 - Rev 02
Substance No.: 2759

Related Databases
  • FDA Inspections
    0 View
  • EDQM CEP
    8 View
  • KDMF
    0 View
  • Japan DMF
    3 View
  • Eudra GMP
    0 View
Official Source

All data is sourced from the official EDQM CEP database (Certification of Suitability to the European Pharmacopoeia).

Visit EDQM
Record Details Preview

Click "View Details" on any record above to expand full details inline.

Country

India

Identifiers

Certificate No.: R1-CEP 2016-309 - Rev 00
Substance No.: 2445

100% Official Data

Directly from the EDQM CEP database

Regular Updates

Data updated regularly from official sources

Trusted by Professionals

100K+ pharma professionals worldwide

Secure & Reliable

Enterprise-grade security and data protection

CEP data is obtained from the official EDQM (European Directorate for the Quality of Medicines) database.

Create a New Buying Request

Fields marked with * are mandatory.

Please enter quantity.
Please select a unit.
Please select quality standard.
Please select request type.
Please provide product specifications.
Please enter additional details.
Please select shipping preference.
Notice: By submitting this buying request, the provided product details and requirements may be published publicly on our marketplace.